These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1444098)

  • 1. Detection of regulatory factors of lymphokine-activated killer cell activity in head and neck cancer patients treated with interleukin-2 and interferon alpha.
    Clayman GL; Young G; Taylor DL; Savage HE; Lavedan P; Schantz SP
    Ann Otol Rhinol Laryngol; 1992 Nov; 101(11):909-15. PubMed ID: 1444098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa.
    Clayman GL; Liu FJ; Savage HE; Taylor DL; Lavedan P; Buchsbaum RM; Pellegrino C; Trujillo JM; Young G; Schantz SP
    Arch Otolaryngol Head Neck Surg; 1992 Jan; 118(1):41-8. PubMed ID: 1370199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.
    Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP
    Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer.
    Wanebo HJ; Blackinton D; Kouttab N; Mehta S
    Am J Surg; 1993 Oct; 166(4):389-94. PubMed ID: 8214299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
    Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
    Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation of the induction phase of lymphokine-activated killer activity by acute phase proteins.
    Clayman GL; Liu FJ; Taylor DL; Savage HE; Lavedan P; Buchsbaum RM; Trujillo JM; Schantz SP
    Otolaryngol Head Neck Surg; 1991 Jul; 105(1):26-34. PubMed ID: 1715542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer.
    Bugis SP; Lotzová E; Savage HE; Hester JP; Racz T; Sacks PG; Schantz SP
    Cancer Immunol Immunother; 1990; 31(3):176-81. PubMed ID: 2337906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
    Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
    Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
    Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
    Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
    Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
    Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
    Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
    Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.